RPG Life Sciences Unveils Naprosyn ES: A Game-Changer for Pain Management in India

RPG Life Sciences Limited has launched Naprosyn ES, introducing India’s first fixed-dose combination of Naproxen and Esomeprazole for the treatment of chronic pain and inflammatory conditions. The product has been launched in partnership with Archerchem Healthcare and is designed to provide effective pain relief while reducing the risk of gastrointestinal side effects commonly associated with long-term NSAID therapy.

The launch strengthens RPG Life Sciences’ portfolio in chronic care and reinforces its focus on developing differentiated, patient-centric healthcare solutions.

A New Approach to Chronic Pain Management

Patients requiring long-term treatment with Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) often face the challenge of balancing pain relief with the risk of stomach irritation, ulcers, and other gastrointestinal complications.

Naprosyn ES combines:

• Naproxen – a widely used anti-inflammatory and pain-relieving medicine.
• Esomeprazole – a proton pump inhibitor that helps reduce stomach acid and protects the gastrointestinal tract.

By combining both medicines into a single tablet, the product aims to improve patient convenience, treatment adherence, and long-term safety.

Partnership with Archerchem Healthcare

The product has been developed through a strategic collaboration with Archerchem Healthcare, which specializes in complex pharmaceutical formulations.

Under the partnership, RPG Life Sciences will have exclusive rights to market and distribute Naprosyn ES across India through its extensive sales and distribution network.

The collaboration combines Archerchem’s formulation expertise with RPG Life Sciences’ strong presence among physicians and healthcare professionals nationwide.

Management Highlights Innovation

Commenting on the launch, Ashok Nair, Managing Director of RPG Life Sciences, said the introduction of Naprosyn ES reflects the company’s research-driven approach toward developing differentiated therapies and further strengthens the trusted Naprosyn brand in India.

Anil Dhedia, Chairman & Managing Director of Archerchem Healthcare, stated that the partnership demonstrates the companies’ commitment to delivering meaningful pharmaceutical innovation that improves medication adherence and enhances patient outcomes.

Expanding Chronic Care Portfolio

The launch of Naprosyn ES aligns with RPG Life Sciences’ long-term strategy of expanding its presence in chronic therapy segments through innovative products that address unmet medical needs.

With chronic pain conditions becoming increasingly common due to ageing populations and lifestyle-related disorders, the demand for safer and more convenient treatment options continues to grow.

By introducing India’s first Naproxen-Esomeprazole combination, RPG Life Sciences aims to offer physicians and patients an advanced treatment option that delivers effective pain management while helping protect gastrointestinal health.

Key Highlights